Searching for optimal decisions and revising management tactics for patients with endometriosis

1. Chapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019; 15: 666-82. https://doi.org/10.1038/s41574-019-0245-z.
2. http://endometriosis.org/news/support-awareness/world-endometriosis-organisations-weo-represents-200-million-with-endometriosis-globally
3. Ghiasi M., Kulkarni M.T., Missmer S.A. Is endometriosis more common and more severe than it was 30 years ago? J. Minim. Invasive Gynecol. 2020; 27(2): 452-61. https://doi.org/10.1016/j.jmig.2019.11.018.
4. Szamatowicz M., Hermanowicz-Szamatowicz K. Endometriosis – a decade later – still an enigmatic disease. What is the new in the diagnosis and treatment? Gynecol. Endocrinol. 2020; 36(2): 104-8. https://doi.org/10.1080/09513590.2019.1675045.
5. Johnson N.P., Hummelshoj L.; for the World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum. Reprod. 2013; 28(6): 1552-68. https://doi.org/10.1093/humrep/det050.
6. Dunselman G.A., Vermeulen N., Becker C. et al.; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12. https://doi.org/10.1093/humrep/det457.
7. Kuznetsov L., Dworzynski K., Davies M. et al. Diagnosis and management of endometriosis: summary of NICE guidance. BMJ. 2017; 358: j4227. https://doi.org/10.1136/bmj.j4227.
8. Koninckx P.R., Ussia A., Adamyan L. et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil. Steril. 2019; 111: 327-40. https://doi.org/10.1016/j.fertnstert.2018.10.01.
9. Gallagher C.S., Mäkinen N., Harris H.R. et al. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. Nat. Commun. 2019; 10(1): 4857. https://doi.org/10.1038/s41467-019-12536-4.
10. Mafra F., Mazzotti D., Pellegrino R. et al. Copy number variation analysis reveals additional variants contributing to endometriosis development. J. Assist. Reprod. Genet. 2017; 34(1): 117-24. https://doi.org/10.1007/s10815-016-0822-1.
11. Méar L., Herr M., Fauconnier A. et al. Polymorphisms and endometriosis: a systematic review and meta-analyses. Hum. Reprod. Update. 2020; 26(1): 73-102. https://doi.org/10.1093/humupd/dmz034.
12. Bulun S.E., Yilmaz B.D., Sison C. et al. Endometriosis. Endocr. Rev. 2019; 40: 1048-79. https://doi.org/10.1210/er.2018-00242.
13. Chantalat E., Valera M.-C., Vaysse C. et al. Estrogen receptors and endometriosis. Int. J. Mol. Sci. 2020; 21: 2815. https://doi.org/10.3390/ijms21082815.
14. García-Gómez E., Vázquez-Martínez E.R., Reyes-Mayoral C. et al. Regulation of inflammation pathways and inflammasome by sex steroid hormones in endometriosis. Front. Endocrinol. (Lausanne). 2019; 10: 935. https://doi.org/10.3389/fendo.2019.00935.
15. Grandi G., Mueller M.D., Papadia A. et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J. Reprod. Immunol. 2016; 117: 30-8. https://doi.org/10.1016/j.jri.2016.06.004.
16. Nanda A., Thangapandi K., Banerjee P. et al. Cytokines, angiogenesis, and extracellular matrix degradation are augmented by oxidative stress in endometriosis Ann. Lab. Med. 2020; 40(5): 390-7. https://doi.org/10.3343/alm.2020.40.5.390.
17. Markham R., Luscombe G.M., Manconi F., Fraser I.S. А detailed profile of pain in severe endometriosis. J. Endometr. Pelvic Pain Disord. 2019; 11(2): 85-94. https://doi.org/10.1177%2F2284026519838948.
18. Nezhat C., Vang N., Tanaka, P.P., Nezhat C. Optimal management of endometriosis and pain. Obstet. Gynecol. 2019; 134(4): 83-9. https://doi.org/10.1097/AOG.0000000000003461.
19. Ball E., Khan K.S. Recent advances in understanding and managing chronic pelvic pain in women with special consideration to endometriosis. F1000Res. 2020; 9: F1000 Faculty Rev-83. https://doi.org/10.12688/f1000research.20750.1.
20. Coxon L., Horne A.W., Vincent K. Pathophysiology of endometriosis-associated pain: A review of pelvic and central nervous system mechanisms. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 53-67. https://doi.org/10.1016/j.bpobgyn.2018.01.014.
21. McKinnon B.D., Bertschi D., Bersinger N.A., Mueller M.D. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol. Metab. 2015; 26(1): 1-10. https://doi.org/10.1016/j.tem.2014.10.003.
22. Forster R., Sarginson A., Velichkova A. et al. Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and nerve-sensitizing factor in pain associated with endometriosis. FASEB J. 2019; 33(10): 11210-22. https://doi.org/10.1096/fj.201900797R.
23. Grundström H., Gerdle B., Alehagen S. et al. Reduced pain thresholds and signs of sensitization in women with persistent pelvic pain and suspected endometriosis. Acta Obstet. Gynecol. Scand. 2019; 98(3): 327-36. https://doi.org/10.1111/aogs.13508.
24. Nisenblat V., Bossuyt P.M., Shaikh R. et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2016; (5): CD012179.
25. Knific T., Fishman D., Vogler A. et al. Multiplex analysis of 40 cytokines do not allow separation between endometriosis patients and controls. Sci. Rep. 2019; 9(1): 16738.
26. Coutinho L.M., Ferreira M.C., Rocha A.L.L. et al. New biomarkers in endometriosis. Adv. Clin. Chem. 2019; 89: 59-77. https://doi.org/10.1016/bs.acc.2018.12.002.
27. Gao Y., Shen M., Ma X. et al. Seven hormonal biomarkers for diagnosing endometriosis: meta-analysis and adjusted indirect comparison of diagnostic test accuracy. J. Minim. Invasive Gynecol. 2019; 26(6): 1026-35. https://doi.org/10.1016/j.jmig.2019.04.004.
28. Gupta D., Hull M.L., Fraser I. et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2016; (4):CD012165.
29. Madjid T.H., Ardiansyah D.F., Permadi W., Hernowo B. Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in endometriosis menstrual blood. Diagnostics (Basel). 2020; 10(6): E364.https://doi.org/10.3390/diagnostics10060364.
30. Verket N.J., Falk R.S., Qvigstad E. et al. Development of a prediction model to aid primary care physicians in early identification of women at high risk of developing endometriosis: cross-sectional study. BMJ Open. 2019; 9: e030346. https://doi.org/10.1136/bmjopen-2019-030346.
31. Nisenblat V., Bossuyt P.M., Farquhar C. et al. Imaging modalities for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2016; (2): CD009591. https://doi.org/10.1002/14651858.CD009591.pub2.
32. Deslandes A., Parange N., Childs J.T. et al. Current status of transvaginal ultrasound accuracy in the diagnosis of deep infiltrating endometriosis before surgery: a systematic review of the literature. J. Ultrasound Med. 2020; Online Version. https://doi.org/10.1002/jum.15246.
33. Moura A.P.C., Ribeiro H.S.A., Bernardo W.M. et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis: Systematic review and meta-analysis. PLoS One. 2019; 14(4): e0214842. https://doi.org/10.1371/journal.pone.0214842.
34. Tong A., VanBuren W.M., Chamié L. et al. Recommendations for MRI technique in the evaluation of pelvic endometriosis: consensus statement from the society of abdominal radiology endometriosis disease-focused panel. Abdom. Radiol. 2020; 45: 1569-86. https://doi.org/10.1007/s00261-020-02483-w.
35. Chapron C., Vannuccini S., Santulli P. et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum. Reprod. Update. 2020; 26(3): 392-411. https://doi.org/10.1093/humupd/dmz049.
36. Tellum T., Nygaard S., Lieng M. Noninvasive diagnosis of adenomyosis: a structured review and meta-analysis of diagnostic accuracy in imaging. J. Minim. Invasive Gynecol. 2020; 27(2): 408-18. https://doi.org/10.1016/j.jmig.2019.11.001.
37. Angioni S., Cofelice V., Pontis A. et al. New trends of progestins treatment of endometriosis. Gynecol. Endocrinol. 2014; 30(11): 769-73. https://doi.org/10.3109/09513590.2014.950646.
38. Barra F., Scala C., Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin. Drug Metab. Toxicol. 2018; 14(4): 399-415. https://doi.org/10.1080/17425255.2018.
39. Abdul Karim A.K., Shafiee M.N., Abd Aziz N.H. et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol. Endocrinol. 2019; 35(1): 10-6. https://doi.org/10.1080/09513590.2018.1490404.
40. Angioni S., Pontis A., Malun M.E. et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol. Endocrinol. 2020; 36(1): 84-6. https://doi.org/10.1080/09513590.2019.1640674.
41. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017; 107: 533-6. https://doi.org/10.1016/j.fertnstert.2017.01.0.
42. Seracchioli R., Mabrouk M., Manuzzi L. et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum. Reprod. 2009; 24(11): 2729-35. https://doi.org/10.1093/humrep/dep259.
43. Yong P.J., Alsowayan N., Noga H. et al. CHC for pelvic pain in women with endometriosis: ineffectiveness or discontinuation due to side-effects. Hum. Reprod. Open. 2020; 2020(2): hoz040. https://doi.org/10.1093/hropen/hoz040.
44. Becker C.M., Gattrell W.T., Gude K., Singh S.S. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil. Steril. 2017; 108: 125-36.
45. Vercellini P., Eskenazi B., Consonni D. et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum. Reprod. Update. 2011; 17: 159-70. https://doi.org/10.1093/humupd/dmq042.
46. Chapron C., Souza C., Borghes B. et al. Oral Contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011; 26(8): 2028-35. https://doi.org/10.1093/humrep/der156.
47. Laganà A.S., Vitale S.G., Granese R. et al. Clinical dynamics of dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin. Drug Metab. Toxicol. 2017; 13(6): 593-6. https://doi.org/10.1080/17425255.2017.1297421.
48. Murji A., Biberoğlu K., Leng J. et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020; 36(5): 895-907. https://doi.org/10.1080/03007995.2020.1744120.
49. Miyashita M., Koga K., Takamura M. et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol. 2014; 30: 644-8. https://doi.org/10.3109/09513590.2014.911279.
50. Mita S., Shimizu Y., Sato A. et al. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil. Steril. 2013; 101(2): 595-601. https://doi.org/10.1016/j.fertnstert.2013.10.038.
51. Hayashi A., Tanabe A., Kawabe S. et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res. 2012; 5: 31. https://doi.org/10.1186/1757-2215-5-31.
52. Grandi G., Mueller M., Bersinger N.A. et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res. 2016; 65(3): 183-92. https://doi.org/10.1007/s00011-015-0909-7.
53. Kitawaki J., Kusuki I., Yamanaka K., Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(2): 212-6. https://doi.org/10.1016/j.ejogrb.2011.03.012.
54. Adachi K., Takahashi K., Nakamura K. et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol. 2016; 32(8): 646-9. https://doi.org/10.3109/09513590.2016.1147547.
55. Chandra A., Rho A.M., Jeonget K. et al. Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma. Obstet. Gynecol. Sci. 2018; 61(1): 111-7. https://doi.org/10.5468/ogs.2018.61.1.111.
56. Lee J.H., Song J.Y., Yi K.W. et al. Effectiveness of dienogest for treatment of recurrent endometriosis: multicenter data. Reprod. Sci. 2018; 25(10): 1515-22. https://doi.org/10.1177/1933719118779733.
57. Koshiba A., Mori T., Okimura H. et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J. Obstet. Gynaecol. Res. 2018; 44(10): 1970-6. https://doi.org/10.1111/jog.13725.
58. Del Forno S., Mabrouk M., Arena A. et al. Dienogest or norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery? Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 238: 120-4. https://doi.org/10.1016/j.ejogrb.2019.04.010.
59. Berlanda N.P., Somigliana E., Frattaruolo M.P. et al. Surgery versus hormonal therapy for deep endometriosis: is it a choice of the physician? Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 209: 67-71. https://doi.org/10.1016/j.ejogrb.2016.07.513.
60. Yela D., Kajikawa P., Donati L. et al. Deep infiltrating endometriosis treatment with dienogest: a pilot study. J. Endometr. Pelvic Pain Disord. 2015; 7(1): 33-7. https://doi.org/10.5301/je.5000202.
61. Leonardo-Pinto J.P., Benetti-Pinto C.L., Cursino K. et al. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 211: 108-11. https://doi.org/10.1016/j.ejogrb.
62. Donnez J., Dolmans M.-M., Fellah L. What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? Fertil. Steril. 2019; 111(3): 454-6. https://doi.org/10.1016/j.fertnstert.2018.12.018.
63. Chapron C., Tosti C., Marcellin L., Bourdon M., Lafay-Pillet M.C., Millischer A.E. et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum. Reprod. 2017; 32(7): 1393-401. https://doi.org/10.1093/humrep/dex088.
64. Hirata T., Izumi G., Takamura M. et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol. Endocrinol. 2014; 30(10): 726-9. https://doi.org/10.3109/09513590.2014.926882.
65. Fawzy M., Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch. Gynecol. Obstet. 2015; 292(6): 1267-71. https://doi.org/10.1007/s00404-015-3755-5.
66. Osuga Y., Fujimoto-Okabe H., Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind,multicenter, placebo-controlled study. Fertil. Steril. 2017; 108(4): 673-8. https://doi.org/ 10.1016/j.fertnstert.2017.07.021.
67. Techatraisak K., Hestiantoro A., Ruey S. et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under reallife clinical practice. Women’s Health. 2019; 19: 68. https://doi.org/10.1186/s12905-019-0758-6.

Received 31.07.2020

Accepted 05.08.2020